PIK3CA突变-话题@MedSci

#PIK3CA突变#

9篇内容 | 1278人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2208437, encodeId=cc15220843ee0, content=<a href='/topic/show?id=1751448167b' target=_blank style='color:#2F92EE;'>#妇科癌症#</a> <a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a> <a href='/topic/show?id=1de211522305' target=_blank style='color:#2F92EE;'>#阿培利司#</a>, objectTitle=阿培利司在PIK3CA突变晚期妇科癌症中显示出有前景的临床活性, objectType=article, longId=828643, objectId=a9ff82864393, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240604/1717483954638_1608702.png, objectUrl=/article/show_article.do?id=a9ff82864393, replyNumber=0, likeNumber=62, createdTime=2024-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a9ff82864393, moduleTitle=阿培利司在PIK3CA突变晚期妇科癌症中显示出有前景的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9ff82864393)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2169027, encodeId=a6db216902efe, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a> , objectTitle=8%的恶性肿瘤、32%的乳腺癌存在PIK3CA突变，有什么靶向药？耐药怎么办？, objectType=article, longId=800594, objectId=e97c800594b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-researcher-looking-through-the-microscope-64JFWLH.jpg, objectUrl=/article/show_article.do?id=e97c800594b9, replyNumber=0, likeNumber=112, createdTime=2023-11-17, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e97c800594b9, moduleTitle=8%的恶性肿瘤、32%的乳腺癌存在PIK3CA突变，有什么靶向药？耐药怎么办？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e97c800594b9)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1710581, encodeId=3f681e1058133, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=81, createdTime=2022-01-06, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710579, encodeId=a08f1e10579aa, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, objectType=article, longId=205897, objectId=fcad20589ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad20589ed6, replyNumber=0, likeNumber=98, createdTime=2021-09-13, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad20589ed6, moduleTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcad20589ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710580, encodeId=2acf1e1058094, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好, objectType=article, longId=209307, objectId=690420930ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690420930ed9, replyNumber=0, likeNumber=98, createdTime=2021-06-24, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690420930ed9, moduleTitle=JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=690420930ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710578, encodeId=2ff31e105789b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批, objectType=article, longId=198589, objectId=2f9119858915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9119858915, replyNumber=0, likeNumber=100, createdTime=2021-01-27, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9119858915, moduleTitle=也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f9119858915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710577, encodeId=f23d1e105778b, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌, objectType=article, longId=167492, objectId=4e2216e4929e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2216e4929e, replyNumber=0, likeNumber=71, createdTime=2020-04-08, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2216e4929e, moduleTitle=FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2216e4929e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710576, encodeId=27971e10576cc, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, objectType=article, longId=156162, objectId=125715616238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125715616238, replyNumber=0, likeNumber=70, createdTime=2019-08-25, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125715616238, moduleTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125715616238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710574, encodeId=19131e10574e3, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, objectType=article, longId=120634, objectId=1dba1206345c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dba1206345c, replyNumber=0, likeNumber=92, createdTime=2018-02-04, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dba1206345c, moduleTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dba1206345c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, objectTitle=CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤, objectType=article, longId=137692, objectId=2bc713e69248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bc713e69248, replyNumber=0, likeNumber=95, createdTime=2018-11-04, rootId=0, userName=ms6323715314570549, userId=617b31881621, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bc713e69248, moduleTitle=CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bc713e69248)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PIK3CA突变

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#妇科癌症# #PIK3CA突变# #阿培利司#

阿培利司在PIK3CA突变晚期妇科癌症中显示出有前景的临床活性

2024-06-05发表于上海

(审核中...)

前往app查看评论内容

#PIK3CA突变#

8%的恶性肿瘤、32%的乳腺癌存在PIK3CA突变，有什么靶向药？耐药怎么办？

2023-11-17发表于上海

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2022-01-06

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效

2021-09-13

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好

2021-06-24

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批

2021-01-27

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌

2020-04-08

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌

2019-08-25

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌

2018-02-04

ms6323715314570549 (审核中...)

前往app查看评论内容

#PIK3CA突变#

CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤

2018-11-04

科室
- - 订阅+
  - 更多科室
工具
服务